AsiaNet 89261

MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire=KYODO JBN/ --

   -- Silicon Valley investor Khosla Ventures joins esteemed group of global

     investors backing Turn

Turn Biotechnologies, a company developing novel RNA medicines for untreatable

age-related conditions, today announced that it has closed its latest round of

funding. The company has the support of investors focused on identifying and

backing enterprises that have the potential to change the world with their

disruptive technologies.

Khosla Ventures, with a history of investing in "Black Swan" ideas that offer

significant upside, became the newest investor in Turn, joining the Shanda

Group and Formic Ventures. These firms have stakes in cutting-edge Asian,

European and North American companies and are credited with investing in

tipping point companies worldwide.

"Turn sits at the convergence of several areas of recent dramatic innovation,

namely in delivery of RNA as a therapeutic, understanding of cellular

senescence, and cellular reprogramming," said Alex Morgan, MD, PhD, Partner at

Khosla Ventures. "This technology out of Stanford University is on track to

creating novel therapeutics to help heal and rejuvenate age-damaged tissues."

Khosla, Shanda Group and Formic Ventures join Turn's early investors,

Methuselah Fund and Methuselah Foundation, which specialize in companies

committed to extending healthy lifespans and improving quality of life as we

age.

"These investments by funds with a reputation for picking winners around the

world recognize Turn's innovation, vision and potential to disrupt the market,"

said CEO Anja Krammer. "As the population ages, millions of elderly persons are

forced to cope with age-related conditions for which only symptomatic treatment

exists.  Our new investors enable Turn to bring to the market the promise of a

technology that has the potential to improve quality of life and change

healthcare economics globally."

Turn focuses on the repair of tissue at the cellular level, utilizing its

patent-pending mRNA platform technology, ERA™, to combat the effects of aging

in the epigenome, thus restoring optimal gene expression and enabling cells to

function as vigorously as younger cells. This restores the cells' ability to

prevent or treat disease and heal or regenerate tissue.

Use of mRNA, which led to the quick development of two COVID-19 vaccines

approved for use in the United States, promises to revolutionize the

development of therapeutics by making that development safer, faster, more

efficient and extremely tunable to patient need.

Turn's epigenetic reprogramming technology has the potential to significantly

impact a wide variety of age-related diseases, and the company is currently

exploring treatments for dermatologic, osteoarthritic, ophthalmic and muscular

conditions. Its work in these areas has also attracted several potential

partners, which are currently in discussions with Turn.

ABOUT TURN BIOTECHNOLOGIES

Turn is a pre-clinical-stage company focused on repairing tissue at the

cellular level. The company's proprietary mRNA technology combats the effects

of aging in the epigenome, thus restoring optimal gene expression and enabling

cells to function as vigorously as when they were younger. Turn's technology

provides a platform from which to attack a variety of diseases related to age.

The company is currently completing pre-clinical research on tailored therapies

targeting indications in dermatology, ophthalmology, osteo-arthritis and

cartilage damage and musculature. For more information, see www.turn.bio.

ABOUT KHOSLA VENTURES

Khosla Ventures provides venture assistance and strategic advice to

entrepreneurs working on breakthrough technologies. The firm was founded by

Vinod Khosla, co-founder of Sun Microsystems, and focuses on transformative

technology in consumer, enterprise, education, financial services, health, big

data, agriculture/food, sustainable energy and robotics. For more information,

see www.khoslaventures.com.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or +1 (312) 543-9026

or

Wendy Dolwig, Turn Biotechnologies

wendy.dolwig@turn.bio

SOURCE: Turn Biotechnologies, Inc.